Harry J M Groen Selected Research

ErbB Receptors (EGF Receptor)

4/2023	Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study.
1/2022	A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the Netherlands.
4/2021	Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
1/2021	Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC.
11/2020	Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.
2/2020	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations.
1/2019	Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.
10/2018	Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.
11/2017	Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
1/2015	Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Harry J M Groen Research Topics

Disease

83	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 11/2002
62	Neoplasms (Cancer) 01/2024 - 02/2002
28	Lung Neoplasms (Lung Cancer) 01/2024 - 05/2004
15	Disease Progression 02/2021 - 04/2009
12	Chronic Obstructive Pulmonary Disease (COPD) 05/2024 - 03/2010
12	Neoplasm Metastasis (Metastasis) 05/2023 - 02/2003
8	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2016
5	Emphysema 04/2023 - 02/2014
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 04/2021 - 06/2006
4	Circulating Neoplastic Cells 12/2019 - 07/2015
4	Hypoxia (Hypoxemia) 01/2017 - 12/2012
3	Adenocarcinoma of Lung 11/2021 - 01/2016
3	Fatigue 01/2021 - 11/2017
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 05/2013
3	Pain (Aches) 01/2021 - 02/2013
2	Cough 01/2023 - 01/2021
2	Sarcoma (Soft Tissue Sarcoma) 04/2021 - 08/2013
2	Diarrhea 02/2021 - 11/2017
2	Vomiting 02/2021 - 10/2017
2	Neutropenia 01/2021 - 01/2019
2	Malignant Mesothelioma 01/2021 - 05/2013
2	Thrombocytopenia (Thrombopenia) 01/2019 - 08/2004
2	Adenocarcinoma 01/2018 - 01/2011
2	Mesothelioma 01/2017 - 05/2013
2	Pneumonia (Pneumonitis) 06/2005 - 05/2004
2	Radiation Pneumonitis 05/2004 - 07/2003
1	Retinoblastoma (Glioblastoma, Retinal) 01/2022
1	Asthma (Bronchial Asthma) 01/2022
1	Leukopenia 10/2021
1	Hyperglycemia 02/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Infections 01/2021
1	Asthenia 01/2021

Drug/Important Bio-Agent (IBA)

15	Biomarkers (Surrogate Marker)IBA 01/2024 - 08/2005
12	ErbB Receptors (EGF Receptor)IBA 04/2023 - 06/2010
12	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2022 - 06/2010
10	Tyrosine Kinase InhibitorsIBA 04/2023 - 08/2013
10	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 08/2004
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2002
9	PlatinumIBA 02/2021 - 06/2002
8	Gemcitabine FDA Link 02/2021 - 07/2003
7	DNA (Deoxyribonucleic Acid)IBA 03/2022 - 01/2017
7	CrizotinibIBA 01/2020 - 02/2015
6	Circulating Tumor DNAIBA 08/2023 - 10/2018
6	Pemetrexed (MTA)FDA Link 02/2021 - 04/2009
6	Bevacizumab (Avastin)FDA Link 01/2019 - 01/2011
5	Docetaxel (Taxotere)FDA Link 10/2021 - 08/2004
5	Paclitaxel (Taxol)FDA LinkGeneric 02/2021 - 11/2007
5	AfatinibIBA 11/2020 - 09/2014
5	Cisplatin (Platino)FDA LinkGeneric 11/2017 - 06/2002
4	Cell-Free Nucleic AcidsIBA 08/2023 - 01/2015
4	RNA (Ribonucleic Acid)IBA 05/2023 - 01/2015
4	Anaplastic Lymphoma KinaseIBA 01/2022 - 02/2015
4	Etoposide (VP 16)FDA LinkGeneric 01/2021 - 11/2007
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 04/2006
4	Gefitinib (Iressa)FDA Link 11/2020 - 09/2014
4	dabrafenibIBA 01/2020 - 01/2016
4	Phosphotransferases (Kinase)IBA 01/2017 - 06/2010
3	GoldIBA 03/2024 - 01/2013
3	Messenger RNA (mRNA)IBA 05/2023 - 09/2013
3	osimertinibIBA 04/2023 - 01/2020
3	Tobacco Smoke Pollution (Passive Smoking)IBA 12/2022 - 04/2020
3	brigatinibIBA 09/2022 - 08/2017
3	Immune Checkpoint InhibitorsIBA 11/2021 - 12/2018
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2011
3	trametinibIBA 01/2020 - 07/2016
3	RadiopharmaceuticalsIBA 01/2017 - 02/2002
3	CalciumIBA 01/2015 - 12/2010
2	AsbestosIBA 05/2024 - 01/2022
2	B7-H1 AntigenIBA 01/2024 - 10/2019
2	capmatinibIBA 01/2023 - 01/2020
2	ORALIT (ORS)IBA 01/2022 - 04/2020
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2021 - 01/2019
2	veliparibIBA 01/2021 - 01/2019
2	ParaffinIBA 10/2020 - 08/2013
2	Formaldehyde (Formol)FDA Link 10/2020 - 08/2013
2	LigandsIBA 12/2018 - 08/2003
2	Epithelial Cell Adhesion MoleculeIBA 10/2018 - 07/2015
2	Cetuximab (Erbitux)FDA Link 11/2017 - 09/2014
2	fluoroazomycin arabinosideIBA 11/2014 - 08/2013
2	Sorafenib (BAY 43-9006)FDA Link 02/2013 - 06/2010
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2013 - 03/2010
2	Angiogenesis InhibitorsIBA 01/2011 - 08/2005
2	Epirubicin (Ellence)FDA LinkGeneric 06/2010 - 05/2004
2	2',2'-difluoro-2'-deoxyuridineIBA 06/2010 - 06/2010
1	Bronchodilator Agents (Bronchodilators)IBA 03/2024
1	NivolumabIBA 05/2023
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 04/2021
1	erythromycin propionate-N-acetylcysteinateIBA 04/2021
1	rociletinibIBA 02/2021
1	Antineoplastic Agents (Antineoplastics)IBA 01/2021
1	FluorineIBA 01/2021

Therapy/Procedure

31	Therapeutics 01/2024 - 12/2003
21	Drug Therapy (Chemotherapy) 10/2022 - 12/2003
14	Radiotherapy 01/2021 - 07/2003
7	Immunotherapy 01/2024 - 01/2017
4	Cranial Irradiation 01/2022 - 10/2018
3	Thoracotomy 02/2013 - 04/2006
2	Adjuvant Chemotherapy 01/2019 - 02/2013
1	Combination Drug Therapy (Combination Chemotherapy) 01/2024